SCHEMBL15687283

SCHEMBL15687283

CCOCc1n[nH]c2cc(C(=O)OC)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 2/20 0.48
KIF11 P52732 1/20 0.46
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
PARP1 P09874 3/20 0.43
DYRK1A Q13627 1/20 0.43
RAB9A P51151 1/20 0.42
CSNK2A1 P68400 1/20 0.42
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CHEK1 O14757 1/20 0.41
CDK7 P50613 1/20 0.41
PKM P14618 2/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15687608 0.88 MAP2K4 (0.51) MAP2K4KIF11KDM4EALDH1A1HSD17B10
SCHEMBL3603266 0.87 MAP2K4 (0.52) MAP2K4KIF11KDM4EALDH1A1HSD17B10
SCHEMBL15687750 0.85 MAP2K4 (0.48) MAP2K4KIF11KDM4EALDH1A1HSD17B10
SCHEMBL28818149 0.79 KMT2A (0.47) MAP2K4KIF11KDM4EALDH1A1HSD17B10
SCHEMBL2671565 0.76 MAP2K4 (0.59) MAP2K4KIF11KDM4EALDH1A1HSD17B10
SCHEMBL30159687 0.76 MAP2K4 (0.56) MAP2K4KIF11KDM4EALDH1A1HSD17B10
SCHEMBL4404846 0.76 MAP2K4 (0.56) MAP2K4KIF11KDM4EALDH1A1HSD17B10
SCHEMBL1501576 0.76 MAP2K4 (0.56) MAP2K4KIF11KDM4EALDH1A1HSD17B10
SCHEMBL31750236 0.76 MAP2K4 (0.56) MAP2K4KIF11KDM4EALDH1A1HSD17B10
SCHEMBL4899295 0.76 MEN1 (0.50) MAP2K4KIF11KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988379-B2 GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent LG CHEM, LTD. (KR) 2018-06-05 US disclosed
US-20150291584-A1 GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT LG CHEM, LTD. (KR) 2015-10-15 US disclosed
EP-2917180-A1 GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT LG Life Sciences Ltd. (KR) 2015-09-16 EP disclosed
WO-2014073904-A1 GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT LG LIFE SCIENCES LTD. (KR) 2014-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291584-A1 GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT GPR119, GPR65, GPR55 MAP2K4 2487/4885KIF11 3932/4885KDM4E 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.